Brickell Biotech (BBI) will release quarterly earnings on Thursday

Brickell Biotech (BBI) will release quarterly earnings on Thursday


Brickell Biotech (NASDAQ: BBI – Get Rating) will release its earnings data after the market close on Thursday, May 12. Analysts expect Brickell Biotech to post earnings of ($ 0.06) per share for the quarter.

Brickell Biotech (NASDAQ: BBI – Get Rating) last released its quarterly earnings data on Tuesday, March 15. The company posted ($ 0.06) EPS for the quarter, beating the ($ 0.09) consensus estimate of $ 0.03. Brickell Biotech had a negative return on equity of 163.84% and a negative net margin of 9,770.79%. During the same quarter last year, the company reported earnings per share ($ 0.15). On average, analysts expect Brickell Biotech to post $ 0 EPS for the current fiscal year and $ 0 EPS for the next fiscal year.

Shares of BBI opened at $ 0.24 on Friday. Brickell Biotech has a 12-month low of $ 0.20 and a 12-month high of $ 1.04. The stock has a 50-day moving average price of $ 0.26 and a 200-day moving average price of $ 0.29. The company has a market cap of $ 28.17 million, a PE ratio of -0.45 and a beta of 0.12.

Several brokers recently commented on BBI. William Blair began coverage on Brickell Biotech in a report on Tuesday, March 8. They established an “outperform” score for the company. Zacks Investment Research upgraded Brickell Biotech from a “hold” rating to a “buy” rating and set a $ 0.25 price target for the company in a report on Wednesday, March 23. Finally, HC Wainwright began coverage on Brickell Biotech in a report on Tuesday, Jan.18. They set a “buy” rating and a $ 2.00 price target for the company.

A number of hedge funds recently changed their holdings in the stock. Renaissance Technologies LLC increased its stake in Brickell Biotech by 120.3% in Q4. Renaissance Technologies LLC now owns 3,035,283 shares in the company worth $ 695,000 after acquiring an additional 1,657,479 shares during the last quarter. Geode Capital Management LLC increased its stake in Brickell Biotech by 11.4% in Q3. Geode Capital Management LLC now owns 627,294 shares in the company worth $ 451,000 after acquiring an additional 63,982 shares during the last quarter. Two Sigma Advisers LP increased its stake in Brickell Biotech by 54.8% in Q3. Two Sigma Advisers LP now owns 245,900 shares of the company worth $ 177,000 after acquiring an additional 87,100 shares during the last quarter. Virtu Financial LLC acquired a new position in Brickell Biotech in Q4 valued at $ 51,000. Finally, BlackRock Inc. increased its stake in Brickell Biotech by 239.4% in Q4. BlackRock Inc. now owns 215,682 shares of the company worth $ 49,000 after acquiring an additional 152,138 shares in the last quarter. Institutional investors own 14.99% of the company’s shares.

About Brickell Biotech (Get evaluation)

Brickell Biotech, Inc, a clinical stage pharmaceutical company, is engaged in the development of various prescription drugs for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironio bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent interferon gene inhibitor stimulator for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.

Further reading

Earnings History for Brickell Biotech (NASDAQ: BBI)



Get news and ratings for Brickell Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Brickell Biotech and related companies with MarketBeat.com’s FREE daily newsletter.

.

Leave a Comment

Your email address will not be published.